Thermo Fisher Scientific - Young Chemists Webinar Series
PRMA Consulting - Precision Medicine On-demand Webinar

C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Techno Trends

TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.

First-of-its-Kind SYFOVRE™ (pegcetacoplan injection) Developed for Geographic Atrophy (GA)

Apellis Pharmaceuticals developed SYFOVRE™ (pegcetacoplan injection) for the treatment of secondary age-related macular degeneration (AMD). SYFOVRE™ (pegcetacoplan injection) is the only therapy approved for geographic atrophy (GA). By targeting C3, pegcetacoplan is designed to provide comprehensive control...

Abbisko Therapeutics Discovered Novel CSF-1R Inhibitor Pimicotinib (ABSK021)

Abbisko Therapeutics discovered novel CSF-1R inhibitor Pimicotinib(ABSK021) for the treatment of tenosynovial giant cell tumour (TGCT) patients not responding to surgery. Pimicotinib is the first new generation CSF-1R drug candidate in the world. It is a novel, oral, highly selective and highly potent small molecule inhibitor of CSF-1R. Several studies have shown...

Loxo@Lilly Discovered Novel Jaypirca™ (pirtobrutinib) for Adult Patients

Loxo@Lilly the oncology unit of Eli Lilly and Company discovered novel Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Jaypirca is the first and only BTK inhibitor specifically discovered for patients with mantle cell lymphoma...

Novel IBI351 (KRASG12C Inhibitor) Discovered for the Treatment of Advanced Non-Small Cell Lung Cancer

Innovent Biologics, Inc. Discovered novel IBI351/GFH925(KRASG12C Inhibitor) as monotherapy for the patients previously treated with advanced non-small cell lung cancer. It is applicable for patients with KRASG12C mutation who have received at least one prior line of systemic therapy....

Efruxifermin, Novel Therapy Discovered for Nonalcoholic Steatohepatitis (NASH)

Akero Therapeutics, discovered novel Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH). Efruxifermin (EFX) also known to be AKR-001, currently being evaluated in the ongoing Phase 2b HARMONY study is the main leading candidate for NASH...

Novel Avacincaptad Pegol Developed for Geographic Atrophy

IVERIC bio, Inc developed avacincaptad pegol to treat geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitorhave shown positive results from the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal...

Pfizer Developed Elranatamab for Relapsed or Refractory Multiple Myeloma

Pfizer Inc, developed investigational elranatamab a cancer immunotherapy for the treatment of indivuduals with relapsed or refractory multiple myeloma (RRMM). Elranatamab is bindedwith B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), present on the surface of multiple myeloma (MM) cells, and the CD3 receptor found...

First-of-its-Kind Setmelanotide Discovered for Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc discovers first-of-its-kind setmelanotide for the treatment of obesity. Setmelanotide is not indicated for treating patients with suspected obesity due to POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign. It is also not indicated for obesity related...

Novel Ivonescimab (PD-1/VEGF Bispecific Antibody Developed for Non-Small-Cell Lung Carcinoma (NSCLC) patients

Akeso Biopharma developed novel Ivonescimab (PD-1/VEGF bispecific antibody in combination with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients. Novel Ivonescimab is applicable for patients who have failed to respond to prior PD-(L)1...

Breakthrough CMG901 Drug Introduced for Advanced Gastric Cancer

Connoya introduced CMG901, novel drug for the treatment of Claudin 18.2-positive advanced gastric cancer. This new drug is indicated after first-line or treatment failure or intolerance. CMG901 previously granted orphan drug designation and fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory gastric cancer...

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA Medical Fair Thailand 2023 Thermo Fisher Scientific - Biobank Thermo Fisher Scientific - QualTrak Thermo Fisher Scientific - Gibco solutions CPHI Japan and Pharma IT & Digital Health Expo 2023 PDA Europe Training INTERPHEX 2023 CPHI & PMEC China 2023